Quick Answer
Cardiff Oncology, Inc. reported Operating Income of -$48.96 million for fiscal year 2025.
Cardiff Oncology, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$48.96M | -0.6% |
| 2024 | -$48.65M | -7.1% |
| 2023 | -$45.41M | -13.8% |
| 2022 | -$39.90M | -38.3% |
| 2021 | -$28.86M | -51.2% |
| 2020 | -$19.09M | -14.4% |
| 2019 | -$16.68M | +2.2% |
| 2018 | -$17.05M | +33.4% |
| 2017 | -$25.60M | +36.2% |
| 2016 | -$40.15M | -58.8% |
| 2015 | -$25.27M | -69.1% |
| 2014 | -$14.95M | -39.8% |
| 2013 | -$10.69M | -120.5% |
| 2012 | -$4.85M | -62.9% |
| 2011 | -$2.98M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.97M | +5.0% | +19.0% |
| June 30, 2025 | -$14.78M | -17.8% | -2.7% |
| March 31, 2025 | -$14.38M | -31.5% | -14.1% |
| September 30, 2024 | -$12.60M | -16.5% | -0.4% |
| June 30, 2024 | -$12.54M | -2.8% | -14.7% |
| March 31, 2024 | -$10.93M | +9.3% | -1.0% |
| September 30, 2023 | -$10.82M | -20.3% | +11.4% |
| June 30, 2023 | -$12.21M | -16.9% | -1.3% |
- Cardiff Oncology, Inc. showed a decrease of -0.6% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Cardiff Oncology, Inc.’s operating income has declined by 1544.7% (from -$2.98 million to -$48.96 million).
- The most recent figure is from Cardiff Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: